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PREVENTION OF VENOUS THROMBOEMBOLISM AFTER HIP AND 
 
KNEE REPLACEMENT AMONG OLDER ADULTS 
 
DARAE KO 
 
ABSTRACT 
 
Background: Venous thromboembolism (VTE) after total hip and knee 
replacement is a major patient safety threat, and pharmacologic prophylaxis is 
generally recommended. However, clinicians disagree on the optimal prophylaxis 
agent.  
Objective: We sought to compare effectiveness and safety of aspirin versus 
anticoagulants for VTE prophylaxis after hip and knee replacement.  
Methods: We identified patients aged ≥ 65 years undergoing elective hip and 
knee replacement during 2011–2013 in 59 hospitals nationwide and included in 
the Institute for Health Metrics clinical database. We limited our analysis to the 
patients with electronic medical record of discharge prophylaxis medication. 
Patients were categorized into either anticoagulant or aspirin only group. VTE, 
major hemorrhage, cardiovascular event, and death were identified from 
electronic databases and validated by physician review of the source documents. 
We compared the 90-day risk of VTE and the composite outcome (VTE, 
cardiovascular events, major hemorrhage, and death) in the anticoagulant group 
to the aspirin group using Cox proportional hazards analysis.  
Results: Study sample included 5648 patients with mean age 73 years. The 
overall number of outcome events was low. There were 35 VTE events (0.61%), 
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15 (0.26%) cardiovascular events, 17 major hemorrhages (0.30%), and 18 
deaths (0.31%). In multivariable analysis adjusting for patient demographics and 
cardiovascular disease and risk factors, anticoagulation therapy was associated 
with decreased risk of VTE (HR 0.76, 95% CI 0.35–1.68) and the composite 
outcome (HR 0.80, 95% CI 0.48–1.32) although not statistically significant.  
Conclusion: Among older adults undergoing elective total hip and knee 
replacement in community hospitals, the 90-day risk of VTE and the composite 
outcome was low. We did not find any statistical difference in the risk of the 
outcomes between anticoagulation and aspirin. Future studies with a larger 
sample size and different patient population are needed to validate our results.  
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INTRODUCTION 
Total hip and knee replacement surgeries pose the highest risk for venous 
thromboembolism (VTE). Approximately half of patients develop VTE after hip 
and knee replacement without pharmacologic prophylaxis, and 5% become 
symptomatic1,2. One form of VTE, Pulmonary embolism (PE) is associated with 
30-day all-cause mortality rates of 9 – 11%3. Among the patients who survive the 
acute phase, the long-term morbidity of PE is substantial; 50% of the patients 
report functional decline in the ensuing years4 and 1.5 – 5% develop chronic 
thromboembolic pulmonary hypertension within 2 years3,5. Thirty percent of 
patients with isolated deep vein thrombosis (DVT), another form of VTE, develop 
post-thrombotic syndrome within 5 years5. Given the mortality and long-term 
morbidity of VTE, professional societies now universally recommend 
pharmacologic prophylaxis following hip and knee replacement1,6. However, 
there is currently a lack of consensus on the optimal prophylaxis strategy, leaving 
the average clinician unguided in making a prophylaxis selection. Therefore, this 
thesis examined the association between prophylactic medications and VTE 
outcomes among patients undergoing hip and knee replacement. 
The most significant disagreement between the American College of Chest 
Physicians (ACCP) and the American Academy of Orthopedic Surgeons (AAOS) 
lies in the role of aspirin for post-orthopedic surgery prophylaxis. Until recently, 
the ACCP guideline has specifically recommended against the use of aspirin for 
VTE prophylaxis after hip and knee replacement and instead recommended use 
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of anticoagulation regimens. In contrast, the orthopedic community believes that 
high intensity pharmacologic options such as anticoagulants increase the risk of 
post-operative bleeding and that aspirin 325mg twice daily can be effective when 
combined with early mobilization and mechanical prophylaxis. The lack of 
consensus on the optimal prophylaxis strategy is in large part due to our lack of 
understanding of the safety and effectiveness of the prophylaxis agents in “real-
world” medically complex, older populations. Although data from randomized 
controlled trials are available and are considered highest quality evidence, 
clinical translation of the trial data is challenging because the trial samples are 
younger, healthier, have lower bleeding risk and fall risk, and are more likely to 
be medication adherent compared to “real-world” patients. 
In the current study, we sought to resolve the uncertainty surrounding the 
optimal prophylaxis regimen in clinical practice by comparing effectiveness and 
safety of aspirin versus anticoagulants for VTE prophylaxis in older adults 
undergoing hip and knee replacement in community hospitals.  We compared the 
risk of VTE, major hemorrhage, cardiovascular events, and all-cause mortality 
over a 90-day period in these two classes of prophylactic medications. We 
hypothesized that anticoagulation therapy (i.e. anticoagulant only or 
anticoagulant plus aspirin) would be associated with reduced risks of VTE 
compared to aspirin alone. In addition, we hypothesized that anticoagulation 
therapy would be associated with reduced risk of composite outcomes of VTE, 
major hemorrhage, cardiovascular events, and all-cause mortality due to its 
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efficacy in prevention of VTE, cardiovascular events, and death.  
 
METHODS 
Study Sample 
We included patients aged 65 years or older who underwent elective hip or 
knee replacement at a hospital within the Institute for Health Metrics data system 
over a 30-month period from January 1, 2011 to September 30, 2013. The 
Institute for Health Metrics data system worked with 65 community hospitals 
across the U.S. during the study period. Patients were eligible for the study if 
they had elective hip or knee replacement identified by primary International 
Classification of Diseases (ICD)-9 procedure codes (81.51 for total hip and 81.54 
for total knee replacement) or by chart review (Figure 1). Patients with hip 
fracture, revision or repeat surgery, or bilateral surgery were excluded given that 
these patients represent a unique risk profile for VTE. Patients who experienced 
VTE, major hemorrhage, cardiovascular events, and death prior to discharge 
also were excluded from these analyses. We limited our analysis to the patients 
with electronic medical record (physicians discharge text summary) of discharge 
prophylaxis medication.  
 
Data Collection and Validation 
In addition to the ICD-9 codes, we reviewed clinical information available 
within the Institute for Health Metrics data system, which includes information on 
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laboratory results, drugs administered, radiology reporting, nursing, physical 
therapy, and physicians notes (e.g. admissions, discharge, and daily progress 
notes) as well as claims data. All outcome events were validated by one (major 
hemorrhage, cardiovascular events, and death) or two (VTE) independent 
physician reviewers.  
The Boston University Institutional Review Board approved the study. IHM 
works with clinical data under a HIPAA Business Associates Agreement and is 
permitted by contract to use aggregated, de-identified data for clinical research 
 
Independent variable 
The discharge VTE prophylaxis medications were classified as 
anticoagulation or aspirin (reference) group. The anticoagulation group included 
fondaparinux, NOACs, low molecular weight heparin, and warfarin. The aspirin 
group included aspirin as well as other antiplatelet agents including prasugrel, 
clopidogrel, ticagrelor, and persantine. In cases where there were multiple 
anticoagulants administered, the medication with the highest bleeding risk was 
assigned as the independent variable. If a patient received an anticoagulant and 
aspirin, the patient was assigned to the anticoagulant group.  
 
90-Day Outcome Variables 
VTE – Patients with imaging evidence of PE (ventilation and perfusion scan 
or computed tomography pulmonary angiogram) or DVT (ultrasound with 
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Doppler) or who were treated with an anticoagulant if there were no imaging 
studies available within 90-days post-discharge were coded as having 
experienced VTE. Patients without any imaging evidence of VTE or not treated 
for VTE with an anticoagulant were coded as “no VTE.” 
Major hemorrhage was defined using the International Society of Thrombosis 
and Hemostasis definition of non-surgical major hemorrhage, which includes 
clinical overt hemorrhage 1) leading to death or 2) occurs in critical anatomical 
sites such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, 
pericardial, or intramuscular spaces or 3) leads to decline in hemoglobin level of 
≥ 20 g/L or transfusion of 2 or more units of packed red blood cells7. Patients who 
experienced any one of these conditions within 90-days post-discharge were 
coded as having experienced major hemorrhage. Patients who did not meet 
these criteria were coded as “no major hemorrhage.” 
Cardiovascular event – Patients who experienced stroke, myocardial 
infarction, and cardiac arrest within 90-days post-discharge were coded as 
having experienced a cardiovascular event. Those who did not experience any of 
these events were coded as “no cardiovascular event.” For stroke, we included 
all types and required imaging evidence with CT or MRI. For myocardial 
infarction, we required documentation of troponin elevation, electrocardiogram 
changes, or interventions for myocardial infarction.  
Death was defined as all-cause mortality within 90-days post-discharge. The 
information was obtained from the IHM dataset.  
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Composite outcome included VTE, major hemorrhage, cardiovascular events, 
and death. For patients who experienced more than one outcome event in the 
90-day follow-up period, follow-up ended when the outcome events occurred for 
the first time.  
 
Covariates 
Covariates were abstracted from ICD-9 codes and chart review. Demographic 
variables included age (per year and ≥ 80 years vs. < 80 years), sex (female vs. 
male), and race (white vs. non-white). Medical comorbidities variables included 
hypertension (yes/no), diabetes mellitus (yes/no), hyperlipidemia (yes/no), atrial 
fibrillation (yes/no), heart failure (yes/no), coronary artery disease (yes/no), 
chronic obstructive pulmonary disease (yes/no), peripheral vascular disease 
(yes/no), liver disease (yes/no), kidney disease, history of cancer (yes/no), mean 
length of stay (per day). Cardiovascular risk factors variable (yes/no) included the 
presence of hypertension or diabetes mellitus, or hyperlipidemia. Cardiovascular 
disease variable (yes/no) included the presence of atrial fibrillation, heart failure, 
or coronary artery disease.  
 
Statistical analysis 
Descriptive statistics  
We compared the patient demographics and baseline comorbidities between 
the anticoagulant and aspirin groups using t-tests for continuous variables and 
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chi-square tests for categorical variables. As a secondary analysis, we tested for 
a linear trend in the use of discharge prophylaxis across the study years using 
the Mantel-Haenszel chi-square test.     
 
Association between the prophylaxis medication and the 90-day outcomes and 
adjustment for confounders 
Outcome events were prospectively identified from the date of discharge. 
Follow-up ended when any of the outcome events occurred for the first time. 
Otherwise, patients were censored at 90-days post discharge. We conducted 
Cox proportional hazards regression analyses to assess unadjusted and 
adjusted hazards ratios (HR) and 95% confidence intervals (CI) for VTE and the 
composite outcomes. In our multivariable model, we adjusted for standard risk 
factors associated with cardiovascular outcomes: age, sex, hypertension, 
diabetes mellitus, hyperlipidemia, heart failure, coronary artery disease, and 
chronic kidney disease. These covariates are associated with increased risk of 
the cardiovascular end points, bleeding, and all-cause death. In addition to the 
standard risk factors, we adjusted for covariates that changed the measure of 
association by ≥ 10% using backward selection. In order to identify patients who 
may be at highest risk of experiencing the outcomes, we conducted a stratified 
analysis for age ≥ 80 years vs. < 80 years and used a multiplicative interaction 
term.  All our analyses were conducted using SAS, version 9.4; SAS Institute, 
Cary, North Carolina. 
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RESULTS 
Patient Demographics and Baseline Comorbidities 
We initially identified 12,290 eligible patients using the ICD-9 codes and chart 
review. Of these, 5843 patients met the inclusion and exclusion criteria for the 
surgery types and had electronic medical record of discharge prophylaxis 
medication available. Of those, 104 patients were excluded due to experiencing 
one of the outcomes during their in-hospital stay and 74 were excluded because 
they did not receive any pharmacologic prophylaxis. Our final analytic sample 
included 5648 patients who received known pharmacologic prophylaxis after 
elective hip and knee replacement, and they represented 59 hospitals within the 
Institute for Health Metrics data system from 29 states across the U.S. (Figure 
1).  
The majority of patients (n = 4596, 81.4%) received an anticoagulant with or 
without aspirin. (Table 1). Overall, patients had a mean age of 73.3 (± 6.3) years 
and 18.2% were 80 years of age or older. The majority of the sample were 
women (61.2%) and white (95.5%). Mean length of hospital stay was 3.1 (±1.4) 
days. As expected, there was a high burden of cardiovascular disease and risk 
factors among our older adult sample, ranging from 5.4% for kidney disease to 
71% for hypertension. Approximately three-quarters of the sample had at least 
one cardiovascular risk factor and nearly a quarter had a pre-existing 
cardiovascular disease. 
Compared to the aspirin group, patients who received an anticoagulant were 
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significantly older (73.4 vs. 73.1 years), less likely to be white (96.2 vs. 96.5%) 
and more likely to have a cardiovascular risk factor (77.7 vs. 74.1%) and 
cardiovascular disease (23.8 vs. 18.1%). Hospital length of stay for the 
anticoagulant group was longer than that of the aspirin group (3.2 vs. 2.8 days).  
 
Description of Pharmacologic Prophylaxis Exposure 
Among the individual medications within the anticoagulant group, warfarin 
was most commonly prescribed (42.1%), followed by NOAC (19.1%), low 
molecular weight heparin (18.6%), and aspirin (18.6%) during the study period 
(Table 2a). After stratifying by year, we found that all the medications showed a 
significant trend. Notably, the use of NOACs increased from 2.4% in 2011 to 
33.7% in 2013. In contrast, the use of low molecular weight heparin and warfarin 
decreased substantially from 2011 to 2013.  
 
Associations with 90-Day VTE and Composite Outcomes 
The overall number of events was low: there were 35 VTE events (0.61%), 
consisting of 18 PE (0.31%) and 17 DVT (0.40%) events. Major hemorrhage, 
cardiovascular events, and death occurred in 16 (0.28%), 13 (0.23%), and 18 
(0.31%) patients, respectively. There were a total of 69 (1.2%) composite 
outcomes. The proportions of VTE events were 0.59% (95% CI 0.37 – 0.81%) in 
the anticoagulant group and 0.76% (95% CI 0.24 – 1.3%) in the aspirin group. 
The proportions of the composite outcome were 1.1% (95% CI 0.83–1.4%) and 
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1.6% (95% CI 0.85–2.4%) in the anticoagulant and aspirin groups, respectively.  
In unadjusted analysis, patients on an anticoagulant were associated with 
decreased risk of VTE (HR 0.77, 95% CI 0.35 – 1.70) and the composite 
outcome (HR 0.82, 95% CI 0.49 – 1.36) compared to those on aspirin only, but 
the associations were not statistically significant. In multivariable analysis 
adjusting for patient demographics and cardiovascular disease and risk factors, 
patients on anticoagulant prophylaxis experienced decreased risk of VTE (HR 
0.76, 95% CI 0.35–1.68) and the composite outcome (HR 0.80, 95% CI 0.48–
1.32) although not statistically significant (Table 3).  In our stratified analysis, we 
found that the HR for the composite outcome was lower in the ≥ 80 years group 
(HR 0.48, 95% CI 0.19–1.17) compared to the < 80 years group (HR 0.99, 95% 
CI 0.53–1.85), but the confidence intervals overlapped and the p-value for 
interaction was not statistically significant (Appendix I).  
 
DISCUSSION 
In our analysis of medically complex older adults undergoing hip or knee 
replacement in community hospitals, we report that patients who received 
anticoagulation therapy with or without aspirin had a non-statistically significant 
lower risk of VTE and the composite outcome over 90-days post-discharge.  
Our study is the one of the few studies to report the practice patterns and 
outcomes associated with VTE prophylaxis after hip and knee replacement after 
the professional guidelines were updated1,8 and NOACs were approved by the 
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Food and Drug Administration. Recent epidemiological studies have reported a 
wide range of 90-day post-operative VTE risk after total hip and knee 
replacement without specification of in-hospital events (0.17 – 1.9%; Appendix 
II), and the 90-day risk observed in our study (0.61%) is comparable or slightly 
lower compared to what has been reported previously. Differences in the data 
source for the outcomes (chart review with imaging evidence vs. administrative 
diagnosis codes) and the prophylaxis agents (chart review vs. claims data), the 
start of follow-up (before vs. after hospital discharge), the prophylaxis agents 
used, and the baseline risks of VTE in the study samples likely account for the 
variations in the VTE risk.     
In our study, we were unable to determine any statistically significant 
difference in the risk of VTE between anticoagulation prophylaxis and aspirin 
alone due to the low number of VTE events. The most recent observational study 
using administrative database and insurance claims data reported that aspirin 
only was associated with statistically significant reduced risk of VTE in TKR but 
not THR compared to anticoagulant only or anticoagulant plus aspirin9 during 30-
day post-operative follow-up. Similarly, a study from a major orthopedic surgical 
center observed that warfarin was associated with higher risk of VTE compared 
to aspirin10 (Appendix II). Given that anticoagulants and aspirin have different 
mechanisms of action, and the evidence for efficacy of aspirin for prevention of 
venous thromboembolism is inconclusive (as opposed to the key role aspirin and 
other antiplatelet agents play for prevention of arterial thromboembolism), the 
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results of these two studies are difficult to interpret. They may reflect substantial 
residual confounding due to confounding indication, in which patients who were 
deemed low risk for VTE were preferentially prescribed aspirin instead of an 
anticoagulant. In addition, a study based on insurance claims data9 substantially 
underestimates the true proportion of patients who are on aspirin only.   
The description of change in the use of prophylaxis agents over time reflects 
important clinical practice patterns. The finding that 18% of the sample was 
prescribed aspirin as a sole prophylaxis agent after hip and knee replacement is 
a significant departure from past clinical practice11 and may reflect endorsement 
of the professional guidelines and greater acceptance of aspirin among 
clinicians. The dramatic increase in the use of NOACs most likely reflects the 
Food and Drug Administration approval of rivaroxaban in 2011 (10mg daily). In 
our study, by 2013, NOACs replaced warfarin as the most commonly prescribed 
prophylaxis agent.   
There were several potential limitations to our study.  First, we lacked 
sufficient statistical power to examine the individual medications and outcomes 
separately (Appendix III). Low number of VTE events after joint arthroplasty is a 
frequent limitation in studies from the modern era due to shorter length of 
hospital stay after joint arthroplasty, early mobilization, and wider use of peri-
operative anticoagulation and mechanical prophylaxis. But our research confirms 
significant advances toward the CMS goal of "VTE being a never event post-
orthopedic surgery." We identified 11,117 eligible surgeries but limited our study 
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sample to 5,648 surgeries with discharge prophylaxis medication documented by 
physicians discharge text summary (after excluding patients who did not receive 
any pharmacological prophylaxis). Based on our prior analyses, using in-hospital 
prophylaxis as the discharge prophylaxis or relying on Center for Medicare 
Services billing and claims data to abstract data on aspirin use would not have 
been a valid methodology to determine the exposure variable.  Second, clinical 
translation of the composite end point may be limited due to inclusion of multiple 
end points that represent both efficacy and safety of antithrombotic therapy. 
Although exclusion of the individuals with in-hospital events and multivariable 
adjustment may ameliorate the bias, confounding by indication likely plays a 
major role in assessing safety and effectiveness of anticoagulation therapy. 
However, in our unpublished analysis, we found that choice of prophylaxis 
agents was associated only with the individual hospital and not with baseline 
patient comorbidities. Accounting for hospital clustering in future analyses may 
help reduce bias in prophylaxis choice.      
Our study has several major strengths. We determined the pharmacologic 
prophylaxis agent patients were discharged with by carefully reviewing electronic 
medical records. This allowed us to obtain accurate information on aspirin use, 
which is often purchased over-the-counter and cannot be accurately captured by 
insurance billing or claims data. Use of pre-specified outcome definitions and 
validation of the outcomes by physicians is an additional strength. By including 
older adults undergoing the orthopedic surgeries in community hospitals, the 
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results of our study are generalizable to the real-world clinical practice. 
Identification of our study sample from a large, multihospital data set further 
enhances the generalizability of our results.   
In conclusion, in our contemporary analysis of older adults undergoing 
elective total hip or knee replacement in community hospitals, we found that 
aspirin and NOACs are commonly used for VTE prophylaxis and the 90-day risk 
of VTE is very low. We were unable to determine any statistical difference in the 
risk of VTE and the composite outcome between anticoagulation prophylaxis and 
aspirin alone due to lack of power. Future studies with larger sample size and 
different patient population are needed to validate our results.  
  
15 
 
 
Figure 1. Flow diagram of study sample selection 
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Table 1. Patient demographics and baseline comorbidities among 5648 total hip and knee replacement patients in the IHM 
dataset 
Characteristics 
Anticoagulant (n=4596) 
Aspirin only*  
(n = 1052) Anticoagulant plus aspirin 
(n=911) 
Anticoagulant only 
(n=3685) 
Demographics 
Age, mean (± SD), years 73.9 (±6.4) 73.2 (± 6.2) 73.1 (± 6.4) 
≥ 80 years 192 (21.1) 643 (17.4) 192 (18.3) 
Women, n (%) 514 (56.4) 2310 (62.7) 635 (60.4) 
White race, n (%) 882 (96.8) 3540 (96.1) 973 (92.5) 
Comorbidities 
Cardiovascular risk factors, n (%) 740 (81.2) 2830 (76.8) 779 (74.1) 
Hypertension, n (%) 685 (75.2) 2601 (70.6) 730 (69.4) 
Diabetes mellitus, n (%) 210 (23.1) 770 (20.9) 202 (19.2) 
Hyperlipidemia, n (%) 222 (24.4) 733 (19.9) 189 (17.8) 
Cardiovascular disease, n (%) 287 (31.5) 805 (21.9) 190 (18.1) 
Atrial fibrillation, n (%) 75 (8.2) 362 (9.8) 45 (4.3) 
Congestive heart failure, n (%) 39 (4.3) 123 (3.3) 21 (2.0) 
Coronary artery disease, n (%) 231 (25.4) 469 (12.7) 151 (14.4) 
Chronic obstructive pulmonary disease, n (%) 37 (4.1) 206 (5.6) 60 (5.7) 
Peripheral vascular disease, n (%) 15 (1.7) 50 (1.4) 15 (1.4) 
 
 
 
 
17 
Characteristics 
Anticoagulant (n=4596) 
Aspirin only*  
(n = 1052) Anticoagulant plus aspirin 
(n=911) 
Anticoagulant only 
(n=3685) 
Liver disease, n (%) 4 (0.4) 14 (0.4) 4 (0.4) 
Kidney disease, n (%) 58 (6.4) 197 (5.4) 49 (4.7) 
Malignancy, n (%) 7 (0.8) 43 (1.2) 11 (1.1) 
Mean length of stay (± SD), days 3.2 (±1.2) 3.2 (± 1.5) 2.8 (± 1.3) 
*Includes other antiplatelet agents (n=18) 
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Table 2. Description of the individual prophylaxis medication use by year among 5648 total hip and knee replacement 
patients in the IHM dataset 
Individual discharge prophylaxis*   All 
N (%) 
2011 
N (%) 
2012 
N (%) 
2013 
N (%) 
P-value for 
trend 
Fondaparinux 92 (1.6) 73 (4.0) 6 (0.3) 13 (0.7) <0.001 
NOAC 1076 (19.1) 45 (2.4) 427 (21.3) 604 (33.8) <0.001 
Low molecular weight heparin 1051 (18.6) 375 (20.4) 404 (20.0) 272 (15.2) <0.001 
Warfarin 2377 (42.1) 911 (49.4) 904 (44.8) 562 (31.5) <0.001 
Aspirin only 1052 (18.6) 439 (23.8) 278 (13.8) 335 (18.8) 0.001 
Total 5648 (100.0) 1843 (100.0) 2019 (100.0) 1786 (100.00)  
*Listed from the most to the least potent
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Table 3.  Unadjusted and adjusted association between the independent variables and outcomes among 5648 total hip and 
knee replacement patients in the IHM dataset 
 
 VTE  Composite outcome 
Independent variables N (%) Unadjusted 
HR (95% CI) 
Adjusted 
HR (95% CI) 
N (%) Unadjusted 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Aspirin only 8 (0.76) 1.0 (Ref) 1.0 (Ref) 17 (1.6) 1.0 (Ref) 1.0 (Ref) 
Anticoagulant 27 (0.59) 0.77 (0.35–1.70) 0.76 (0.35–1.68) 52 (1.1) 0.82 (0.49–1.36) 0.80 (0.48–1.32) 
Covariates       
Age   1.07 (1.02–1.13)   1.02 (0.99–1.06) 
Female sex   0.72 (0.37–1.42)   0.83 (0.54–1.27) 
Hypertension   0.92 (0.43–1.95)   0.99 (0.61–1.62) 
Diabetes   1.17 (0.52–2.64)   1.0 (0.59–1.68) 
Hyperlipidemia   1.34 (0.62–2.94)   1.11 (0.67–1.85) 
Heart failure   0.74 (0.10–5.57)   1.03 (0.37–2.89) 
Coronary artery disease   0.96 (0.38–2.39)   1.44 (0.85–2.44) 
Kidney disease   0.80 (0.18–3.46)   2.15 (1.10–4.21) 
20 
 
 
Appendix I: Adjusted association between anticoagulation therapy vs. aspirin 
(reference) and outcomes among subgroups 
 
 Age Subgroups HR (95% CI) 
VTE ≥ 80 years 0.77 (0.21–2.88) 
 < 80 years 0.78 (0.29–2.09) 
Composite ≥ 80 years 0.48 (0.19–1.17) 
 < 80 years 0.99 (0.53–1.85) 
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Appendix II: Summary of recent observational studies comparing VTE risk between different prophylaxis agents in 
orthopedic joint surgeries 
Author, Year 
Surgery 
Study Period 
Study sample 
Follow-up period 
Prophylaxis agents 
(%) Data source Risk 
Significant findings 
(Multivariable adjusted) 
Ko et al. 
(current) 
Elective THR and TKR 
2011–2013 
5,644 adults, mean age 73 
years, 65 community 
hospitals, U.S.  
90 days post discharge 
Fondaparinux (2) 
NOAC (19) 
LMWH (19) 
Warfarin (42) 
Aspirin only(19) 
Chart review 
(imaging evidence 
reviewed)* 
VTE outcomes 
adjudicated 
PE: 0.32% 
DVT: 0.30% 
VTE: 0.62% 
Anticoagulant associated 
with not-statistically 
significant reduced risk of 
VTE compared to aspirin 
(HR 0.80, 95% CI 0.48–
1.32)  
Chu et al. 
20179 
THR and TKR 
2009–2012 
342,401 adults, 59% aged ≥ 
65 years 
 327 hospitals, U.S. 
30 days post surgery 
Aspirin only (8) 
Warfarin  (30) 
Enoxaparin (37) 
Fondaparinux (<6) 
Dalteparin(<6) 
Dabigatran (<6) 
Rivaroxaban (<6)  
Aspirin and 
anticoagulant (13) 
Administrative 
database, claims 
data 
VTE: 0.78% Aspirin associated with 
reduced risk of VTE in 
TKR (OR 0.34, 95% CI 
0.24–0.48) but not after 
THR (OR 0.82, 95% CI 
0.45–1.51) compared to 
anticoagulant only or 
anticoagulant plus aspirin 
Parvizi et al., 
201712 
Total joint arthroplasty 
2013–2015 
4,651 adults, mean age 64–
65 years 
Aspirin 325mg (69%) 
Aspirin 81mg (31%) 
Chart review 
(imaging evidence 
required) 
PE: 0.13% 
DVT: 0.17% 
VTE: 0.28% 
No statistically significant 
difference between 
325mg and 81mg of 
aspirin (OR 1.62, 95% 
CI0.32–8.2).  
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Author, Year 
Surgery 
Study Period 
Study sample 
Follow-up period 
Prophylaxis agents 
(%) Data source Risk 
Significant findings 
(Multivariable adjusted) 
Single center, U.S. 
90 days post surgery 
Huang et al., 
201610 
Total joint arthroplasty 
2000–2014 
30,270 adults, mean age 
62–66 years 
Single center, U.S 
90 days post surgery 
Warfarin (84%) 
Aspirin (16%) 
Chart review 
(imaging evidence 
required) 
PE: 0.89% 
DVT: 1.1% 
VTE: 1.9% 
 
Warfarin associated with 
higher risk of VTE 
compared to aspirin (OR 
13.7, 95% CI 1.9–98.5) 
Lazo-
Langner  et 
al., 201413 
THR and TKR 
2002–2012 
24,321 adults, median age 
73 years, 12 hospitals in 
Ontario, Canada 
30 days post discharge 
LMWH (47%) 
Rivaroxaban (53%) 
Administrative 
database, claims 
data 
VTE: 0.63% Rivaroxaban associated 
with decreased risk of 
VTE compared to LMWH 
(RR 0.58, 95% CI 0.42–
0.80 
Kapoor et al., 
201314 
THR and TKR 
2002–2009 
24,051 veterans, age ≥ 65 
years, 50% aged ≥ 74, 
Multiple VA centers, U.S.   
90 days post surgery 
NR Administrative 
database  
VTE: 3.8% COPD (OR 1.25, 95% CI 
1.06–1.48) and low 
functional status (lowest 
vs. highest quartile OR 
1.62, 95% CI 0.93–2.90) 
associated with increased 
risk of VTE. 
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Author, Year 
Surgery 
Study Period 
Study sample 
Follow-up period 
Prophylaxis agents 
(%) Data source Risk 
Significant findings 
(Multivariable adjusted) 
IJRC Writing 
Committee, 
201215 
Elective THR and TKR 
2008–2009 
696 adults, mean age 64–
71, single center, Utah 
90 days after surgery  
Warfarin (78%) 
Aspirin (22%) 
Chart review 
(imaging evidence 
reviewed)* 
VTE outcomes 
adjudicated 
PE: 1.4% 
DVT: 1.6% 
VTE: 2.6% 
Aspirin significantly 
associated with higher 
risk of VTE compared to 
warfarin (RR 7.9, 95% CI 
4.1–13.4) 
Jameson et 
al., 201116 
Primary THR 
2003–2008 
108,584 adults, 2/3 of 
patients ≥ 65 years National 
Joint Registry, UK 
90 days after surgery 
LMWH (79%) 
Aspirin (21%) 
Administrative 
database, claims 
data 
PE: 0.68% 
DVT: 0.95% 
VTE: 1.6% 
No statistically significant 
difference between 
LMWH and aspirin in the 
risk of PE (OR 0.94, 95% 
CI, 0.75–1.17), DVT (OR 
0.84, 95% CI 0.70–1.03)  
* Ventilation and perfusion scan or computed tomography pulmonary angiogram for PE and ultrasound with Doppler for DVT  
CI, confidence interval; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; HR, hazards ratio; IJRC, 
Intermountain Joint Replacement Center; LMWH, low molecular weight heparin; NOAC, non-vitamin K oral anticoagulant; OR, odds ratio; 
PE, pulmonary embolism; THR, total hip replacement; TKR, total knee replacement; VTE, venous thromboembolism
 24 
Appendix III:  Sample size required for 80% power with range of OR’s for range of VTE 
risk in anticoagulant vs. aspirin only patients* 
Rate of VTE event in 
Aspirin only OR = 0.8 OR = 0.7 OR = 0.6 OR = 0.5 
0.5% 213,725 88,160 45,710 26,740 
1.0% 106,390 43,900 22,770 13,320 
1.5% 70,615 29,145 15,120 8,850 
2.0% 52,725 21,770 11,295 6,615 
*Note: Sample size calculations are based on the assumption that 80% of patients receive an 
anticoagulant and 20% receive aspirin only, and 2-sided alpha=0.05. 
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